Type 2 Diabetes

Cannabis Use Linked to Quadrupled Diabetes Risk: Study of 4 Million Adults

Cannabis use associated with quadrupled risk of developing type 2 diabetes, finds study of over 4 million adults, is a headline that certainly grabs your attention. It’s like a flashing warning sign, and the immediate thought is, “Woah, is that a real thing?” The study, which is currently only slated to be presented at a scientific conference and hasn’t undergone full peer review, suggests a significant association, but it’s important to unpack what that really means and not jump to conclusions. This study seems to be based primarily on patient-reported cannabis use and epidemiological data, which is a crucial detail to remember.… Continue reading

Ozempic Approved for Chronic Kidney Disease: High Cost and Patent Concerns Emerge

The FDA approved Novo Nordisk’s Ozempic to treat chronic kidney disease in patients with Type 2 diabetes, expanding its use beyond diabetes management. This approval allows Ozempic to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in this patient population. A late-stage trial demonstrated Ozempic significantly reduced severe kidney outcomes by 24%, slowed kidney function decline, and lowered cardiovascular event risk. The approval highlights the broader health benefits of GLP-1 drugs, impacting treatment for comorbid conditions frequently found together.

Read More